Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines.
Ontology highlight
ABSTRACT: Messenger RNA (mRNA)-based vaccines have shown promise against infectious diseases and several types of cancer in the last two decades. Their promise can be attributed to their safety profiles, high potency, and ability to be rapidly and affordably manufactured. Now, many RNA-based vaccines are being evaluated in clinical trials as prophylactic and therapeutic vaccines. However, until recently, their development has been limited by their instability and inefficient in vivo transfection. The nanodelivery system plays a dual function in RNA-based vaccination by acting as a carrier system and as an adjuvant. That is due to its similarity to microorganisms structurally and size-wise; the nanodelivery system can augment the response by the immune system via simulating the natural infection proc
SUBMITTER: Alfagih IM
PROVIDER: S-EPMC7823281 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA